Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CDT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.36
vs -0.00
Q1.23
N/A
-1.17
vs -0.01
Q2.23
N/A
-0.80
vs -0.01
Q3.23
+328%
0.06
vs -0.03
Q4.23
+113%
0.04
vs -0.36
Q1.24
N/A
-0.05
vs -1.17
Q2.24
N/A
-7.00
vs -0.80
Q3.24
N/A
-7.00
vs 0.06
Q4.24
N/A
-20.33
vs 0.04
Q1.25
+100%
NA
vs -0.05
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
535.7M vs NA
Q2.24
NA
604.3M vs NA
Q3.24
NA
244M vs NA
Q4.24
NA
660.7M vs NA
Q1.25
+17%
624.9M vs 535.7M
Return on Equity
QoQ
Q2.23
+16%
0.16
vs 0.17
Q3.23
-184%
-1.84
vs 0.16
Q4.23
-389%
-3.89
vs -1.84
Q1.24
+115%
1.15
vs -3.89
Q2.24
+99%
0.99
vs 1.15
Q3.24
+71%
0.71
vs 0.99
Q4.24
0%
-0.00
vs 0.71
Q1.25
+4%
0.04
vs -0.00
Institutionnal Ownership
QoQ
Q3.23
3
3
vs NA
NA
Q4.23
11
11
vs 3
267%
Q1.24
18
18
vs 11
64%
Q2.24
29
29
vs 18
61%
Q3.24
32
32
vs 29
10%
Q4.24
36
36
vs 32
13%
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
9 hours ago
Relative Strength
CDT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How CDT compares to sector?
CDT
0x
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.02 ( -5.21%)
Relative Strenght
0
Volume Buzz
-82%
Earning Acce
No
Dist 52w H.
100%Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available